国际肿瘤学杂志

国际肿瘤学杂志 ›› 2019, Vol. 46 ›› Issue (4): 199-204.doi: 10.3760/cma.j.issn.1673-422X.2019.04.002

• 论著 • 上一篇    下一篇

长非编码RNA ZEB1-AS1在乳腺癌中的表达及其临床意义

王妮娜,李晓花,陈敏丽,朱勇   

  1. 陕西省宝鸡市中心医院放射治疗科  721008
  • 收稿日期:2018-10-15 修回日期:2019-02-10 出版日期:2019-04-08 发布日期:2019-05-29
  • 通讯作者: 朱勇，Email: zhuyongzbj@sina.cn E-mail:zhuyongzbj@sina.cn

Expression and clinic significance of long non-coding RNA ZEB1-AS1 in breast cancer

Wang Nina, Li Xiaohua, Chen Minli, Zhu Yong   

  1. Department of Radiotherapy, Baoji Central Hospital of Shaanxi Province, Baoji 721008, China
  • Received:2018-10-15 Revised:2019-02-10 Online:2019-04-08 Published:2019-05-29
  • Contact: Zhu Yong, Email: zhuyongzbj@sina.cn E-mail:zhuyongzbj@sina.cn

PDF

431

摘要： 目的  探讨长非编码RNA ZEB1-AS1在乳腺癌中的表达及其临床意义。方法  选取2007年6月至2015年4月陕西省宝鸡市中心医院的130例乳腺癌患者。采用实时荧光定量PCR（qRT-PCR）检测乳腺癌组织及对应癌旁正常组织中ZEB1-AS1的表达量；分析ZEB1-AS1表达量与乳腺癌患者临床特征、生存期之间的关系。通过siRNA技术干扰ZEB1-AS1的表达，采用CCK-8实验、克隆形成实验、Transwell实验检测对照组、siRNA-1组、siRNA-2组乳腺癌细胞株MCF-7的增殖能力、克隆形成能力、迁移能力。结果  ZEB1-AS1在乳腺癌组织中表达量高于对应癌旁正常组织［M(QR)：0.001 6（0.005 1）∶0.000 9（0.001 5）；Z=-4.426，P<0.001］。ZEB1-AS1高表达与乳腺癌患者淋巴结转移（χ2=9.148，P=0.027）、人表皮生长因子受体2阴性（ χ2=5.039，P=0.025）及三阴性乳腺癌（χ2=4.597，P=0.032）相关。ZEB1-AS1高表达患者较低表达患者生存期缩短（χ2=14.340，P＜0.001）。细胞增殖实验结果显示，ZEB1-AS1敲低后72 h，对照组、siRNA-1组、siRNA-2组细胞吸光度值分别为0.605±0.049、0.488±0.054、0.417±0.038，3组间差异有统计学意义（F=15.936，P<0.001），2个干扰组细胞增殖能力均明显较对照组减弱(均P<0.05)。对照组、siRNA-1组、siRNA-2组的细胞克隆数分别为297.5±11.4、192.0±12.1、204.8±12.8，3组间差异具有统计学意义（F=112.526，P<0.001），2个干扰组细胞克隆形成能力均明显较对照组降低（均P<0.001)。对照组、siRNA-1组、siRNA-2组的迁移细胞数分别为184.5±8.6、147.5±18.6、57.6±7.3，3组间差异具有统计学意义（F=12.409，P=0.001），2个干扰组细胞迁移能力均明显较对照组降低（均P<0.001）。结论  ZEB1-AS1在乳腺癌中高表达，且高表达将缩短乳腺癌患者生存期，干扰ZEB1-AS1能够抑制乳腺癌细胞增殖、迁移和克隆形成能力。

关键词: 乳腺肿瘤, 预后, ZEB1-AS1

Abstract: Objective  To detect the expression and clinic significance of long non-coding RNA ZEB1-AS1 in breast cancer. Methods   A total of 130 patients with breast cancer in Baoji Central Hospital of Shaanxi Province from June 2007 to April 2015 were selected. Quantitative real-time PCR (qRT-PCR) was used to detect the expression level of ZEB1-AS1 in breast cancer tissues and corresponding normal tissues, and the relationships between the expression level of ZEB1-AS1 and the clinic characteristics of the patients and their overall survival time were analyzed. siRNA was used to disturb the expression of ZEB1-AS1. CCK-8 assay, clone formation assay and Transwell assay were used to detect the proliferation, cloning ability and migration of breast cancer MCF-7 cells in control group, siRNA-1 group and siRNA-2 group. Results  The expression level of ZEB1-AS1 in breast cancer tissues was higher than that in corresponding normal tissues ［M(QR): 0.001 6 (0.005 1) vs. 0.000 9 (0.001 5); Z=-4.426, P<0.001］. The higher expression of ZEB1-AS1 was correlated with lymphatic metastasis (χ2=9.148, P=0.027), negative human epidermal growth factor receptor 2 (χ2=5.039, P=0.025), triple negative breast cancer (χ2=4.597, P=0.032). The patients with the higher expression of ZEB1-AS1 had a shorter overall survival time compared with the patients with the lower expression of ZEB1-AS1 (χ2=14.340, P＜0.001). CCK-8 assay showed that knock down of ZEB1-AS1 after 72 h, the absorbance values of the control group, siRNA-1 group and siRNA-2 group were 0.605±0.049, 0.488±0.054, 0.417±0.038 respectively, with a statistically significant different (F=15.936, P<0.001), and the two siRNA groups were significantly inhibited in cell proliferation compared with the control group (both P<0.05). The colonies of the control group, siRNA-1 group and siRNA-2 group were 297.5±11.4, 192.0±12.1, 204.8±12.8 respectively, with a statistically significant different (F=112.526, P<0.001), and the two siRNA groups were significantly inhibited in the cell clone compared with the control group (both P<0.001). The migratory cells numbers of the control group, siRNA-1 group and siRNA-2 group were 184.5±8.6, 147.5±18.6, 57.6±7.3 respectively, with a statistically significant different (F=12.409, P=0.001), and the two siRNA groups were significantly inhibited in the cell migration (both P<0.001). Conclusion  ZEB1-AS1 is overexpressed in breast cancer, overexpression of ZEB1-AS1 induces a shorter overall survival in breast cancer patients, and knock down of ZEB1-AS1 can inhibit the proliferation, migration and colony formation ability of the breast cancer cell line.

Key words: Breast neoplasms, Prognosis, ZEB1-AS1